Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

ClinicalTrials.gov ID: NCT07565428

Public ClinicalTrials.gov record NCT07565428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects With Schizophrenia, Followed by a 52-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate of Roluperidone and antipsychotic medications.

Study identification

NCT ID
NCT07565428
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Minerva Neurosciences
Industry
Enrollment
380 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 22, 2026
Primary completion
Nov 30, 2027
Completion
Nov 30, 2028
Last update posted
Jul 27, 2026

2026 – 2028

United States locations

U.S. sites
13
U.S. states
7
U.S. cities
13
Facility City State ZIP Site status
Clinical Innovations, Inc. dba CITrials Bellflower California 90706 Recruiting
ProScience Research Group Culver City California 90230 Recruiting
Collaborative Neuroscience Research, LLC Garden Grove California 92845 Recruiting
Clinical Innovations, Inc. dba CITrials Riverside California 92506 Recruiting
Velocity Clinical Research, Hallandale Beach Hallandale Florida 33009 Recruiting
Behavioral Clinical Research, Inc. Hollywood Florida 33021 Recruiting
ForCare Clinical Research Tampa Florida 33613 Recruiting
Atlanta Center for Medical Research, LLC Atlanta Georgia 30331 Recruiting
CenExel iResearch, LLC Decatur Georgia 30030 Recruiting
CBH Health, LLC dba CenExel Gaithersburg Maryland 20877 Recruiting
Hassman Research Institute, LLC dba CenExel Marlton New Jersey 08053 Recruiting
New York State Psychiatric Institute New York New York 10032 Recruiting
Pillar Clinical Research, LLC Richardson Texas 75080 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07565428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 27, 2026 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07565428 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →